Ryder System, Inc. (R) Shareholders - L&K, LLP Encourages you to File a Claim Against the Settlement Fund Before Deadline
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Ryder System, Inc. (NYSE: R). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Ryder System, Inc. (R) on Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Ryder System, Inc. (NYSE:R). The settlement provides for a fund of $45,000,000 to benefit class members.
Theralase(R) Successfully Destroys Lung Cancer
TORONTO, ON / ACCESSWIRE / June 6, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF) is a clinical stage pharmaceutical company that is dedicated to the research and development of light and/or radiation activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it's lead compound, RuvidarTM, combined with transferrin to form the compound Rutherrin®, has been proven effective preclinically in the destruction of Non-Small Cell Lung Cancer ("NSCLC"). Theralase® recently completed experiments in NSCLC, using a Lewis Lung Cancer ("LLC1") orthotopic model.
Zomedica Announces Presentation of Compelling TRUFORMA(R) Research Findings and Educational Programs at Major Veterinary Internal Medicine Conference
New research data confirms superiority of TRUFORMA's Bulk Acoustic Wave Sensor technology in diagnosing feline hyperthyroidism ANN ARBOR, MI / ACCESSWIRE / June 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the presentation of research highlighting the improved diagnostic capabilities of the TRUFORMA® Bulk Acoustic Wave (BAW) platform when evaluating cats for thyroid disease compared to widely utilized chemiluminescent immunoassay (CLIA) platforms. The presentation, "Evaluation of a Feline-Optimized TSH Assay in Cats with Hyperthyroidism and with Non-Thyroidal Illness," will be given by Dr. Camille Brassard, DVM, IPSAV (Virginia-Maryland Regional College of Veterinary Medicine), at the American College of Veterinary Internal Medicine (ACVIM) Forum being held in Minneapolis, MN June 6 - 8, 2024.
Levi & Korsinsky, LLP Notifies Shareholders of Ryder System, Inc. (R) on Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Ryder System, Inc. (NYSE: R). The settlement provides for a fund of $45,000,000 to benefit class members.
Jackpot Digital Signs 4-Table Deal to Install Jackpot Blitz(R) at Gold Country Casino Resort in California
VANCOUVER, BC / ACCESSWIRE / June 4, 2024 / Jackpot Digital Inc. (the "Company" or "Jackpot") (TSXV:JJ)(TSXV:JJ.WT.B)(TSXV:JJ.WT.C)(OTCQB:JPOTF)(Frankfurt Exchange:LVH3), a leading manufacturer of electronic multiplayer dealerless poker tables, is pleased to announce it has signed a software and license agreement (the "Agreement") to install four (4) of the Company's Jackpot Blitz® dealerless poker machines at Gold Country Casino Resort, located in Oroville, California, USA. Leading up to the signing of the Agreement, the Company successfully obtained the required licensing approvals from Berry Creek Rancheria Gaming Commission, the regulator for Gold Country Casino.
Theralase(R) Technology Effective in Virus Inactivation
TORONTO, ON / ACCESSWIRE / June 4, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it's lead compound, RuvidarTM, has been proven effective in the inactivation of various viruses. The research was completed at the laboratory of Kevin Coombs, Ph.D.
Gryphon Digital Mining set to join Russell Microcap(R) Index
LAS VEGAS, NV / ACCESSWIRE / June 3, 2024 / Gryphon Digital Mining, Inc. (Nasdaq:GRYP) ("Gryphon," the "Company," "we," "our," and "us"), a bitcoin mining company that is independently certified to be 100% renewable and pursuing a negative carbon strategy is poised to join the Russell Microcap® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st. Strategic Growth and Operational Excellence Rob Chang, CEO, President, and a Director of Gryphon, stated, "our inclusion in the Russell Microcap Index underscores the rapid progress we believe Gryphon has made in the capital markets.
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage II
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patients The 2.5-year recurrence-free survival rate of mRNA-4157 (V940) in combination with KEYTRUDA was 74.8% as compared to 55.6% for KEYTRUDA alone, with the benefit observed across exploratory subgroups The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer, in addition to Phase 2 studies in patients with renal cell carcinoma and urothelial carcinoma and a Phase 2/3 study for cutaneous squamous cell carcinoma CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / June 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from a planned analysis from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti-PD-1 therapy, in patients with resected high-risk melanoma (stage III/IV) following complete resection (n=157). With a median follow-up of approximately three years (34.9 months), adjuvant treatment with mRNA-4157 (V940) in combination with KEYTRUDA continued to demonstrate a clinically meaningful and durable improvement in recurrence-free survival (RFS), the primary endpoint of the study, reducing the risk of recurrence or death by 49% (HR [95% CI], 0.510 [0.288-0.906]; two-sided nominal p-value 0.019) compared with KEYTRUDA alone.
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes CAMBRIDGE, MA / ACCESSWIRE / May 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna.
Levi & Korsinsky, LLP Notifies Shareholders of Ryder System, Inc. (R) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / May 30, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Ryder System, Inc. (NYSE: R). The settlement provides for a fund of $45,000,000 to benefit class members.
Why Is Ryder (R) Down 0.9% Since Last Earnings Report?
Ryder (R) reported earnings 30 days ago. What's next for the stock?
